Sciex Joins with Children’s Medical Research Institute to Advance Proteomic Profiling
Sciex has announced it is teaming up with the Children’s Medical Research Institute to help equip The Australian Cancer Research Foundation International Centre for the Proteome of Cancer facility with tools to advance its large‑scale proteomic profiling studies.
Sciex (Framingham, Massachusetts, USA) has announced it is teaming up with the Children’s Medical Research Institute (CMRI) (Sydney, Australia) to help equip The Australian Cancer Research Foundation International Centre for the Proteome of Cancer (ProCan) (Sydney, Australia) facility with tools to advance its largeâscale proteomic profiling studies.
These studies will profile thousands of tumour samples per year, enable discoveries around the causes of cancer, provide guidance on cancer treatment options, and work to produce standard operating procedures for other facilities around the world. ProCan will be established with $10 million in seed money from The Australian Cancer Research Foundation to purchase the Sciex equipment.
Chris Radloff, Global Vice President and General Manager of the LC–MS Business at Sciex, said, “Large-scale proteomics studies have great potential to improve our understanding of cancer at the molecular level, but are subject to significant variability caused in sample preparation, data acquisition, and interpretation. Through our partnership with CMRI and the designation of ProCan as a Sciex Centre of Innovation in Precision Medicine, Sciex solutions reduce that variability and enable higher sample throughput, which will help to accelerate cancer research and precision medicine at large.”
Professor Phil Robinson, Head of the Cell Signalling Unit at CMRI and co-developer of ProCan with Professor Roger Reddel, Head of CMRI’s Cancer Research Unit, commented, “Collaborating with Sciex will enable ProCan to accomplish our vision of one day, delivering a proteomics report on every clinician’s desk. The unique industrial proteomics platform we are developing will unlock the potential of our discoveries and empower us to perform the translation research needed to rapidly identify the cause of each individual cancer”
For more information please visit www.sciex.com
AI and GenAI Applications to Help Optimize Purification and Yield of Antibodies From Plasma
October 31st 2024Deriving antibodies from plasma products involves several steps, typically starting from the collection of plasma and ending with the purification of the desired antibodies. These are: plasma collection; plasma pooling; fractionation; antibody purification; concentration and formulation; quality control; and packaging and storage. This process results in a purified antibody product that can be used for therapeutic purposes, diagnostic tests, or research. Each step is critical to ensure the safety, efficacy, and quality of the final product. Applications of AI/GenAI in many of these steps can significantly help in the optimization of purification and yield of the desired antibodies. Some specific use-cases are: selecting and optimizing plasma units for optimized plasma pooling; GenAI solution for enterprise search on internal knowledge portal; analysing and optimizing production batch profitability, inventory, yields; monitoring production batch key performance indicators for outlier identification; monitoring production equipment to predict maintenance events; and reducing quality control laboratory testing turnaround time.
